CPC A61K 9/7084 (2013.01) [A61F 13/0276 (2013.01); A61K 31/445 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/32 (2013.01); A61K 47/44 (2013.01); A61F 2013/0296 (2013.01); B29D 7/01 (2013.01); B29K 2071/02 (2013.01); B29L 2031/753 (2013.01)] | 7 Claims |
1. A percutaneous absorption preparation for the treatment of dementia comprising a backing layer, a drug-containing layer, and a release liner,
wherein the drug-containing layer of the percutaneous absorption preparation comprises (a) donepezil or a pharmaceutically acceptable salt thereof as an active component, (b) a propylene glycol monocaprylate as a solubilizer, (c) a styrene-isoprene-styrene block copolymer as an adhesive, and (d) a plasticizer,
wherein a ratio of donepezil or the pharmaceutically acceptable salt thereof: the propylene glycol monocaprylate is not less than 1:1.5 by weight,
wherein the styrene-isoprene-styrene block copolymer makes up 10-70 wt % of a total weight of the drug-containing layer, and
wherein the plasticizer (d) is selected from the group consisting of paraffin process oil, naphthalene process oil, aromatic process oil, olive oil, camellia oil, tall oil, castor oil, isopropyl myristate, hexyl lauric acid, mineral oil, octyldodecyl myristate, propylene glycol, and a combination thereof.
|